• 대한본초학회지
• /
• 제34권1호
• /
• pp.13-21
• /
• 2019

Objectives : This clinical trial is performed to investigate the effect of improving the hypersensitivity reaction and the safety of powdered ethanol extract Codonopsis lanceolata (S. et Z.) Trautv. for allergic patients. Methods : This study was randomized, double blinded, placebo-controlled clinical trial. 60 allergic rhinitis subjects were randomly assigned to Treatment group(n=30) and Control group(n=30). They were received the test substance or placebo in their $1^{st}$ and $2^{nd}$ visit, and took it once a day, 1 powder bag per 1 time, for 8 weeks. The freeze dried powder of Codonopsis lanceolata (S. et Z.) Trautv. was mixed with 30% ethanol and the filtrate was collected thrice with constant stirring of the mixture. The placebo was prepared in the same form as the test substance by replacing with corn starch. Total Nasal Symptom Score(TNSS) questionnaires and laboratory tests were performed at the screening and last visit to evaluate the efficacy. And to assess safety, vital signs and adverse events were confirmed at every visit. Statistical analysis about the result was performed using SAS 9.4. Results : In treatment group, there was a significant decrease in B cell after taking the test substance(p<0.005). And there was a statistically significant difference between groups(p<0.005). Changes in nasal symptoms were not statistically significant between groups, and both groups showed statistically significant differences before and after the test(p<0.0001). Also there were no adverse events associated with the clinical trial product. Conclusions : This clinical trial showed that Codonopsis lanceolata (S. et Z.) Trautv. extract was helpful in improving the hypersensitivity reaction in allergic patients without significant side effects.

• Journal of Acupuncture Research
• /
• 제24권3호
• /
• pp.175-185
• /
• 2007

Objectives : The purpose of this study is to evaluate the clinical effect of Moxa-Pellet treatment for nasal symptoms and quality of life(QOL) in patients with allergic rhinitis. Methods: Subjects were voluntarily recruited through newspaper and internet advertisement. In this randomized, single blind and controlled study, experimental group (n=19) received real Moxa-Pellet treatment and control group(n=20) received sham Moxa-Pellet treatment for 3 weeks. Acupuncture points used were $LI_4$, $ST_{36}$, $LU_7$, $GV_{14}$ and $GB_{20}$. Patient's nasal symptoms and QOL were assessed before and after 3 weeks treatment by the Nasal Symptom Scores(NSS) and the Medical Outcomes Study 36-Item Short-Form Health Survey(SF-36). Results : The results were as follows; 1. Among items of NSS, Sneezing' Rhinorrhea' Itching scores and Total Nasal Symptom Scores(TNSS) were significantly improved in experimental group after 3 weeks Moxa- Pellet treatment(p<0.05). In control group, there was no significant difference in all items except Headache item of NSS. 2. Among 8 domains of SF- 36, experimental group showed significant difference in Role-Emotional(RE), Mental Health(MH) and Bodily Pain(Bp) after 3 weeks Moxa- Pellet treatment(p<0.05). Control group showed no significant difference in all domains except one domain(Role limitation-physical). Conclusions: These results suggest that Moxa-Pellet treatment can be applicable to improve nasal symptoms and QOL in the patients with allergic rhinitis. Further long tenn studies on the Moxa-Pellets treatment's sustaining power and safety is needed.

• 대한한방내과학회지
• /
• 제37권6호
• /
• pp.961-977
• /
• 2016

Objectives: This study was designed to analyze the treatment effects of Eunhwayeongyo-tang through retrospective chart reviews. We also checked the correlation between each pair of variables of the symptoms and curative rates of patients with cough. Methods: Thirty-three patients with cough who had satisfied the selection criteria were retrospectively reviewed through their basic medical records, nasal endoscopy, and questionnaires about cough on their first and second visits. The questionnaires used were "The questionnaire on clinical symptoms of cough & sputum", Leicester Cough Questionnaire Korean Version (LCQ-K), Total Nasal Symptom Scores (TNSS), Visual Analog Scale (VAS), and "Cold-heat patterns". The improvement rate, calculated by "The questionnaire on clinical symptoms of cough & sputum" was considered to be clinically effective if reduction of symptoms scored more than 30%. The state of nasopharyngeal mucosa was assessed to categorize the cold-heat patterns of the upper respiratory tract and for diagnosis. Results: According to this study, cough and sputum improved by $57.22{\pm}37.76%$. Most patients (76%) improved significantly after $12.18{\pm}6.59days$ of taking Eunhwayeongyo-tang. The cure rates of 26 patients among the 33 patients were judged as effective. All the mean scores of the questionnaires and the anterior nasal cavity states were significantly improved on the patients' second visits. After $18.39{\pm}15.68days$, 30 patients were completely cured and ended treatment. The nasopharyngeal mucosa states of all patients were categorized as heat patterns. Conclusions: The conditions of the patients with nasopharyngitis significantly improved after taking Eunhwayeongyo-tang. All of the patients had pharyngitis or rhinitis. The cold-heat pattern of nasopharyngeal mucosa was a significant indicator of upper respiratory inflammation diagnosis.

• 대한한방내과학회지
• /
• 제41권6호
• /
• pp.1100-1118
• /
• 2020

Objectives: The purpose of this study was to assess the effects of acupuncture as a treatment for allergic rhinitis (AR). We used a meta-analysis and systematic review to analyze the results of randomized controlled trials (RCTs) that applied acupuncture to AR patients. Methods: The key question assessed the effects of acupuncture on patients with AR, and we included only RCTs. We searched the KoreaMed, NDSL, KMBASE, Koreantk, OASIS, PubMed, EMBASE, and Cochrane databases, with no language restriction. We assessed risk of bias with the Cochrane Risk of Bias tool. The random effects model was used to adjust for the heterogeneity of the included studies, and the effect sizes between two groups were reported as mean differences (MD) and risk ratios (RR). Results: Twelve RCTs were analyzed, with a total of 1788 participants; 824 participants were in the treatment group (i.e., acupuncture) and 964 were in the control group (sham acupuncture, western medicine, or waitlist). The meta-analysis results of 7 RCTs comparing the therapeutic efficacy of acupuncture with that of sham acupuncture showed a statistically significant difference (p<0.05) in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and the Change of Total Nasal Symptom Score (TNSS). The meta-analysis of 4 RCTs comparing the therapeutic efficacy of acupuncture with western medicine showed statistically significant differences (p<0.05) in the RQLQ but not in the changes in effective rate (p>0.05). Conclusions: Acupuncture can be an effective treatment for AR, but more studies are required to enhance the level of evidence and to confirm safety.

• 한국수산과학회지
• /
• 제32권5호
• /
• pp.612-617
• /
• 1999

본 연구는 까나리액젓의 객관적인 품질지표의 설정 및 품질의 등급화를 위한 기초자료를 얻을 목적으로, 일광하에서 18개월 동안 발효$\cdot$숙성시킨 까나리액젓과 시중에서 유통되고 있는 시판 제품 15종을 구입하여 각종 성분들을 분석하고, 그 차이를 비교$\cdot$검토하였다. 까나리액젓의 수분함량은 대조구의 경우 $65.3\%$였으며, 시판제품의 경우 $66.5\~71.0\%$ 범위였고, 회분량은 대조구가 $22.4\%$, 시판제품이 $19.3\~24.6\%$ 범위였다. 조단백 질함량은 대조구의 $11.41\%$에 비해 시판제품이 $4.7\~12.0\%$ 범위로 낮아 액젓의 품질에 큰 영향을 미치는 함질소화합물의 농도가 낮음을 나타내었고, 제조원간에도 상당한 차이를 보였다. 시판제품의 pH는 5.56$\~$6.47 범위로 대조구의 5.01보다 높았으며, 염분함량은 시판제품에서 $24.0\~32.9\%$ 범위로 넓게 나타났고, 대조구 (C)는 $29.6\%$였다. 총질소 및 아미노산성질소함량은 시판제품의 경우 대조구 (각각 1.825g/100ml, 1257.97mg/100ml)보다 낮은 0.781$\~$1.918g/100ml 및 445.9-1037.9mg/100ml 범위로서 제조원에 따라서 큰 차이를 보였고, 그 중에서 M, O사 제품은 현행 멸치액젓의 품질기준에 미달되는 것으로 나타났으며, 총질소함량이 높은 제품이 대체로 아미노산성질소함량도 높았다. 시판제품의 VBN함량은 대조구와 비슷하였으며, TMAO 및 TMA함량은 대조구보다 약간 높은 편이었다. 대조구와 시판제품 모두 ATP, ABP, AMP는 거의 검출되지 알았으며, IMP는 극미량, HxR은 약간 검출되었고, 약 $90\%$ 정도가 Hx과 요산이었다. ATP 관련물질 총량 (IMP+HxR+Hx+요산)도 대조구가 9.022$\mu$mo1/ml로 A사를 제외한 나머지 시판제품의 4.766-8.989$\mu$mo1/ml보다 더 많았다. 색도는 시판제품이 대조구보다 $A_{453}$이 낮았다. 유리아미노산 총량은 시판제품이 3,258.9$\~$6,562.6mg/100ml 범위로서 제조원에 따라 2배 정도의 함량 차이를 보였으며, 대조구는 총량이 7,911.3mg/100낀로 시판제품 (AtoP)의 1.2~2.4배였다. 유리아미노산의 조성은 시판제품이 glutamic acid (평균 $15.7\%$ ), Iysine, alanine, leucine, valine, aspa-rtic acid, isoleucine 등의 순이었고, 대조구는 glutamic acid ($15.2\%$ ), alanine, Iysine, leucine, isoleucine, valine, aspatic acid등의 순으로 나타나 주요 아미노산 종류는 같았다 그리고 이들 아미노산의 함량은 총량의 약 $66\%$ 정도를 차지하였다.